

David Gracie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2211114/publications.pdf>

Version: 2024-02-01

73
papers

2,320
citations

361413

20
h-index

223800

46
g-index

73
all docs

73
docs citations

73
times ranked

2702
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 389-400.	3.7	285
2	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 1635-1646.e3.	1.3	258
3	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 189-199.	8.1	212
4	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 632-642.	8.1	186
5	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 549-561.	3.7	136
6	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 541-551.	0.4	117
7	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1053-1062.	8.1	109
8	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 376-384.e5.	4.4	87
9	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 983.	3.0	84
10	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 491-503.	3.7	69
11	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1976-1987.	12.1	69
12	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 702-712.	0.4	65
13	Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1773-1780.	12.1	61
14	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 117-126.	3.7	56
15	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gut</i> , 2021, 70, 1110-1116.	12.1	49
16	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.4	41
17	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13174.	3.0	37
18	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 63-74.	3.7	36

#	ARTICLE	IF	CITATIONS
19	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 700-707.	1.5	35
20	IBS-like symptoms in patients with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 101.	2.3	31
21	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	1.9	21
22	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1597-1605.	1.9	20
23	Longitudinal follow-up study: effect of psychological comorbidity on the prognosis of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 441-450.	3.7	19
24	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1024-1031.	3.0	18
25	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774473.	3.2	18
26	Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. <i>Gastroenterology</i> , 2022, 163, 190-203.e5.	1.3	17
27	Validation and modification of a diagnostic scoring system to predict microscopic colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1206-1212.	1.5	16
28	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1165-1167.	4.4	16
29	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 324-325.	1.3	14
30	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. <i>Gut</i> , 2021, 70, 218.2-219.	12.1	12
31	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13666.	3.0	11
32	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231983843.	2.5	11
33	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 824-832.	3.7	10
34	The possible risks of proton pump inhibitors. <i>Medical Journal of Australia</i> , 2016, 205, 292-293.	1.7	9
35	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1198.	0.4	8
36	Symbiotics in irritable bowel syndrome – better than probiotics alone?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 485-489.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Ongoing Symptoms in Ulcerative Colitis Patients in Remission. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E4-E5.	1.9	6
38	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. <i>Gastroenterology</i> , 2017, 153, 1444-1445.	1.3	6
39	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14256.	3.0	6
40	Evidence-based management of ulcerative colitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2012, 58, 87-99.	2.2	6
41	Functional Bowel Symptoms in Quiescent Inflammatory Bowel Disease: More Than Just Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2014, 147, 1176-1177.	1.3	5
42	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1061-1062.	4.4	5
43	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 762-763.	3.7	4
44	Amoebic colitis. <i>Diagnostic Histopathology</i> , 2017, 23, 563-565.	0.4	4
45	Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?. <i>Gastroenterology</i> , 2017, 153, 1451-1452.	1.3	3
46	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. <i>Gastroenterology</i> , 2021, 160, 2611-2613.	1.3	3
47	Letter: is there a bi-directional relationship between depression and IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 213-213.	3.7	2
48	Defining the Relationship Between Clinical and Biochemical Disease Activity Indices and Perceived Stress in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1632-1634.	1.3	2
49	Editorial: Using Patient-Reported Outcome Measures in Gastroenterology: PROMISed Land or Road to Nowhere?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1557-1558.	0.4	2
50	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. <i>Gastroenterology</i> , 2016, 151, 762-763.	1.3	2
51	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1638.	4.4	2
52	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. <i>Gastroenterology</i> , 2019, 156, 2345-2347.	1.3	2
53	Mood and Treatment Persistence in Inflammatory Bowel Disease: Time to Consider Integrated Models of Care?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1111-1113.	4.4	2
54	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 440-440.	3.7	1

#	ARTICLE	IF	CITATIONS
55	Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders - brain-gut, gut-brain, or both?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 899-900.	3.7	1
56	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. <i>American Journal of Gastroenterology</i> , 2016, 111, 900-901.	0.4	1
57	Editorial: mesalazine to prevent recurrent acute diverticulitis - the final nail in the coffin. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 461-462.	3.7	1
58	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. <i>American Journal of Gastroenterology</i> , 2018, 113, 773-774.	0.4	1
59	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 572-573.	4.4	1
60	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1000-1001.	4.4	1
61	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 132-139.	1.9	1
62	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. <i>Neurogastroenterology and Motility</i> , 2021, , e14282.	3.0	1
63	Limited Evidence for the Existence of Postdiverticulitis Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1521.	4.4	0
64	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1246-1246.	3.7	0
65	Response to Levenstein and Prantera. <i>American Journal of Gastroenterology</i> , 2016, 111, 1499.	0.4	0
66	Letter: deleterious effects of smoking on postoperative Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1248-1248.	3.7	0
67	Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1268-1269.	3.7	0
68	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1315-1316.	4.4	0
69	Editorial: probiotics in inflammatory bowel disease - wrong organisms, wrong disease, or flawed concepts? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 633-634.	3.7	0
70	Reply. <i>Gastroenterology</i> , 2018, 155, 1652-1653.	1.3	0
71	Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. <i>Gastroenterology</i> , 2019, 157, 1429-1430.	1.3	0
72	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1738-1739.	4.4	0

#	ARTICLE	IF	CITATIONS
73	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. Gastroenterology, 2021, 160, 466-467.	1.3	0